Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 26, 2018
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC) today announced that an abstract, entitled “Effect of Disease Severity on Survival ...
February 26, 2018
BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Gary ...
February 26, 2018
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study
DURHAM, NC / ACCESSWIRE / February 26, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system ...
February 26, 2018
CytoSorbents to Participate at the BTIG Healthcare Conference
MONMOUTH JUNCTION, N.J., Feb. 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and ...
February 26, 2018
Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
February 26, 2018
CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma
BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
February 26, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in ...
February 26, 2018
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene Therapies
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology ...
February 26, 2018
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
Zug, Switzerland, February 26, 2018 - Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
February 23, 2018
Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
MORRISTOWN, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, announced today that the Company will report financial ...
February 23, 2018
DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call
CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (DRRX) fourth quarter 2017 financial results press release, you are invited to listen to ...
February 23, 2018
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC), a leader in the development of innovative therapies intended to significantly ...
February 23, 2018
Addex Publishes Extraordinary General Meeting Invitation
Geneva, Switzerland, 23 February 2018 - Addex Therapeutics (ADXN.SW), the leading developer of oral allosteric modulators for neurological disorders, announced today that it has published ...
February 23, 2018
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Basel, Switzerland, February 23, 2018   Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has commenced enrollment in the first of its two planned clinical phase ...
February 23, 2018
Vermillion to Present at the 2018 BTIG Healthcare Conference
AUSTIN, Texas, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President ...
February 22, 2018
TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 22, 2018
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering ...
February 22, 2018
Santhera Completes Capital Increase to Settle Obtained License from Polyphor
Pratteln, Switzerland, February 22, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that its share capital recorded in the commercial register was increased from 6,279,857 shares by 247,622 ...
February 22, 2018
BioTime Appoints Cavan Redmond to Its Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redmond as an ...
February 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and ...
Page 115 of 169